Model ANKASTIM -Allogenic NK Cell Therapy
FromAlphageneron
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK cells are expanded, and incubated ex vivo with TKD and IL-2, followed by freezing, thawing and intravenous administration to patients.
Most popular related searches
natural killer cell therapy
natural killer cell
cell therapy
preclinical trial
allogeneic cell
immune deficiency
colorectal cancer
clinical study
cancer nsclc
intravenous administration
- Pre-clinical (animal) studies in Germany have demonstrated that TKD/IL-2 activated human allogeneic NK cells control the growth of human metastatic colorectal cancer, NSCLC, and metastatic pancreatic cancer in immune deficient mice. Pre-clinical studies in immune deficient mice have also shown the efficacy of ANKASTIM against human metastatic lung cancer to be further improved when combined with OPDIVO®.
- Planned Phase I clinical Combination trial in metastatic gastric and colorectal cancer (Stage IV) in the United States, after standard of care (SOC) combined with PD(L)-1 checkpoint inhibitor patients, who failed chemo-radiation and PD(L)-1 checkpoint inhibitors as salvage therapy.